CIK 0000873303
- Large accelerated filer
Sarepta Therapeutics, Inc.
Sign in to watch- Ticker
- SRPT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 930797222
- Phone
- +1 617-274-4000
- Business address
- 215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142
- Former names
- Sarepta Therapeutics, Inc., AVI BIOPHARMA INC, ANTIVIRALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-11-16 | Rodino-Klapac Louise Chief Scientific Officer | Grant or award | +40,000 | 61,898 | ||
| 2021-09-08 | Estepan Ian Michael Chief Financial Officer | Shares withheld for taxes | −1,623 | $78.29 | $127K | 26,753 |
| 2021-06-26 | INGRAM DOUGLAS S President & CEO | Shares withheld for taxes | −17,812 | $80.40 | $1.4M | 340,056 |
| 2021-06-01 | Brown Ryan Edward SVP, General Counsel | Shares withheld for taxes | −64 | $76.01 | $5K | 19,368 |
| 2021-03-10 | BEHRENS M KATHLEEN Director | Exercise or conversion | +5,000 | $42.30 | $212K | 135,517 |
| 2021-03-10 | BEHRENS M KATHLEEN Director | Sale | −5,000 | $85.76 | $429K | 130,517 |
| 2021-03-10 | BEHRENS M KATHLEEN Director | Exercise or conversion · Stock Option (right to buy) | −5,000 | 0 | ||
| 2021-03-08 | Wigzell Hans Lennart Rudolf Director | Exercise or conversion | +10,000 | $34.92 | $349K | 26,518 |
| 2021-03-08 | Wigzell Hans Lennart Rudolf Director | Sale | −10,000 | $83.51 | $835K | 16,518 |
| 2021-03-08 | Wigzell Hans Lennart Rudolf Director | Exercise or conversion · Stock Option (right to buy) | −10,000 | 0 | ||
| 2021-03-05 | Estepan Ian Michael Chief Financial Officer | Shares withheld for taxes | −347 | $84.65 | $29K | 28,376 |
| 2021-03-04 | Brown Ryan Edward SVP, General Counsel | Shares withheld for taxes | −190 | $80.76 | $15K | 19,432 |
| 2021-03-03 | O'Neill Gilmore Neil EVP, R&D & CMO | Grant or award | +15,000 | 28,546 | ||
| 2021-03-03 | Brown Ryan Edward SVP, General Counsel | Grant or award | +15,000 | 19,622 | ||
| 2021-03-03 | Rodino-Klapac Louise Chief Scientific Officer | Grant or award | +15,000 | 21,780 | ||
| 2021-03-03 | Estepan Ian Michael Chief Financial Officer | Grant or award | +15,000 | 28,723 | ||
| 2021-03-03 | Wigzell Hans Lennart Rudolf Director | Grant or award | +2,726 | 16,518 | ||
| 2021-03-03 | Wigzell Hans Lennart Rudolf Director | Grant or award · Stock Option (right to buy) | +5,518 | 5,518 | ||
| 2021-03-03 | Rodino-Klapac Louise Chief Scientific Officer | Grant or award | +15,000 | 22,169 | ||
| 2021-03-03 | Rodino-Klapac Louise Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 |
Page 20 of 22 · 424 trades